A Right-First-Time Approach To Viral Vector Manufacturing

By Julien Depollier, PhD, Director Strategic Partnerships at Polyplus

Gene therapies are complexmolecules and require higher volumes of drug product. To create scalable processes that can treat indications that affect large patient populations via systemic administration of high-dose formulations, it is becoming increasingly imperative to design processes right the first time. Accounting for quality and scalability into viral-vector manufacturing processes from the outset is not only more efficient, but also essential to enabling the cost-effective production of large quantities of gene therapies.

Discover how the presented approaches to overcoming current issues limiting the available capacity for viral-vector manufacturing make gene therapies accessible to more patients.